Literature DB >> 29725804

Validation of the EPIPHANY index for predicting risk of serious complications in cancer patients with incidental pulmonary embolism.

Shin Ahn1,2, Tim Cooksley3, Srinivas Banala4, Luke Buffardi5, Terry W Rice6.   

Abstract

PURPOSE: The EPIPHANY index was developed to classify cancer associated pulmonary embolism (PE) into different risk categories using decision tree modeling. In this study, we tried to externally validate this index in a distinct group of patients solely composed of incidental PE (IPE).
METHODS: A retrospective study of patients diagnosed with IPE in two Emergency Departments in the USA and South Korea from 2013 to 2014 was performed. The primary outcome was the occurrence of a serious medical complication within 15 days of presentation to ED. Thirty-day complication was the secondary outcome. Cumulative hazard curves for each prognostic category were drawn to show the change in hazards over time.
RESULTS: A total of 258 patients with IPE were included (193 from MD Anderson Cancer Center and 65 from Asan Medical Center). Serious complication within 15 days occurred in 23 (8.9%) patients. The risk of overall 15-day and 30-day serious complications increased with each category (low, intermediate, and high risk: 3.4, 8.9, and 23.8%, P = 0.033; 6.9, 9.5, and 33.3%, P = 0.011). Cumulative hazard curves for each prognostic category were drawn and the survival functions factored by prognostic categories were significantly different over 15 days (P = 0.015) and 30 days (P = 0.001).
CONCLUSIONS: Our study suggests the EPIPHANY index could be a useful adjunct tool in risk stratification of cancer patients with IPE.

Entities:  

Keywords:  Cancer; Complication; Incidental pulmonary embolism; Oncologic emergencies; Venous thromboembolism

Mesh:

Year:  2018        PMID: 29725804     DOI: 10.1007/s00520-018-4235-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  20 in total

1.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

Authors:  D W BARRITT; S C JORDAN
Journal:  Lancet       Date:  1960-06-18       Impact factor: 79.321

2.  Provider practice models in ambulatory oncology practice: analysis of productivity, revenue, and provider and patient satisfaction.

Authors:  Lori A Buswell; Patricia Reid Ponte; Lawrence N Shulman
Journal:  J Oncol Pract       Date:  2009-07       Impact factor: 3.840

3.  Emergency oncology: development, current position and future direction in the USA and UK.

Authors:  Tim Cooksley; Terry Rice
Journal:  Support Care Cancer       Date:  2016-11-04       Impact factor: 3.603

4.  Prognostic Value of Treatment Setting in Patients With Cancer Having Pulmonary Embolism: Comparison With the Pulmonary Embolism Severity Index.

Authors:  Shin Ahn; Yoon-Seon Lee; Won Young Kim; Kyung Soo Lim; Jae-Lyun Lee
Journal:  Clin Appl Thromb Hemost       Date:  2016-01-11       Impact factor: 2.389

5.  Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: The POMPE-C tool.

Authors:  Jeffrey A Kline; Pierre-Marie Roy; Martin P Than; Jackeline Hernandez; D Mark Courtney; Alan E Jones; Andrea Penaloza; Charles V Pollack
Journal:  Thromb Res       Date:  2012-04-03       Impact factor: 3.944

6.  On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism.

Authors:  A Carmona-Bayonas; C Font; P Jiménez-Fonseca; Francisco Fenoy; R Otero; C Beato; J Plasencia; M Biosca; M Sánchez; M Benegas; D Calvo-Temprano; D Varona; L Faez; M A Vicente; I de la Haba; M Antonio; O Madridano; A Ramchandani; E Castañón; P J Marchena; M J Martínez; M Martín; G Marín; F Ayala de la Peña; V Vicente
Journal:  Thromb Res       Date:  2016-05-12       Impact factor: 3.944

7.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

8.  Incidental venous thromboembolism in oncology patients.

Authors:  A A Khorana; C O'Connell; G Agnelli; H A Liebman; A Y Y Lee
Journal:  J Thromb Haemost       Date:  2012-12       Impact factor: 5.824

9.  Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism.

Authors:  D Aujesky; A Perrier; P-M Roy; R A Stone; J Cornuz; G Meyer; D S Obrosky; M J Fine
Journal:  J Intern Med       Date:  2007-06       Impact factor: 8.989

10.  Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; C Font; F Fenoy; R Otero; C Beato; J M Plasencia; M Biosca; M Sánchez; M Benegas; D Calvo-Temprano; D Varona; L Faez; I de la Haba; M Antonio; O Madridano; M P Solis; A Ramchandani; E Castañón; P J Marchena; M Martín; F Ayala de la Peña; V Vicente
Journal:  Br J Cancer       Date:  2017-03-07       Impact factor: 7.640

View more
  5 in total

1.  Outpatient management of incidental pulmonary embolism in cancer patient.

Authors:  Andrés J Muñoz Martín; Magdalena Carmen Ruiz Zamorano; María Carmen Viñuela Benéitez; Laura Ortega Morán; Ángela García Pérez; Miguel Martín Jiménez
Journal:  Clin Transl Oncol       Date:  2019-06-13       Impact factor: 3.405

Review 2.  Risk stratification for clinical severity of pulmonary embolism in patients with cancer: a narrative review and MASCC clinical guidance for daily care.

Authors:  Diego Muñoz-Guglielmetti; Tim Cooksley; Shin Ahn; Carmen Beato; Mario Aramberri; Carmen Escalante; Carme Font
Journal:  Support Care Cancer       Date:  2022-05-17       Impact factor: 3.359

Review 3.  Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper.

Authors:  Tim Cooksley; Carme Font; Florian Scotte; Carmen Escalante; Leslie Johnson; Ronald Anderson; Bernardo Rapoport
Journal:  Support Care Cancer       Date:  2020-11-23       Impact factor: 3.603

Review 4.  Emergency management of incidental pulmonary embolism (IPE).

Authors:  Carme Font; Tim Cooksley; Shin Ahn; Bernardo Rapoport; Carmen Escalante
Journal:  Emerg Cancer Care       Date:  2022-06-20

Review 5.  Pulmonary Embolism in the Cancer Associated Thrombosis Landscape.

Authors:  Géraldine Poenou; Teona Dumitru Dumitru; Ludovic Lafaie; Valentine Mismetti; Elie Ayoub; Cécile Duvillard; Sandrine Accassat; Patrick Mismetti; Marco Heestermans; Laurent Bertoletti
Journal:  J Clin Med       Date:  2022-09-25       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.